The German group hopes that boosting its presence in gene therapy will drive growth of its pharma business.
The $13.1bn price suggests that Bristol could be banking on mavacamten’s potential outside rare diseases.
The sequencing group’s $8bn deal to recapture Grail leaves shareholders unimpressed.
Merck's move on a target that has attracted little attention – Liv-1 – means future data readouts are now eagerly awaited.
As Immunomedics and Seattle both get backing from the big boys, antibody-drug conjugates finally come of age.
Licensing deal could enable bundling of antipsychotics with management technology.
Abbvie signs up China’s I-Mab instead of Trillium, but several other early-stage contenders are looking at the novel immuno-oncology mechanism.
Yumanity Therapeutics wants to be at the forefront of a neurodegenerative disease revolution, but is taking an unglamorous route to get there.
The $6.5bn price – biopharma’s biggest buyout of the year so far – shows how competitive the anti-FcRn space has become.